Skip to main content
Apeloa Pharmaceutical Co.,Ltd. logo

Apeloa Pharmaceutical Co.,Ltd. — Investor Relations & Filings

Ticker · 000739 ISIN · CNE000000Q45 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,841 across all filing types
Latest filing 2019-10-17 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 000739

About Apeloa Pharmaceutical Co.,Ltd.

https://www.apeloa.com

Apeloa Pharmaceutical Co., Ltd. focuses on the research, development, manufacturing, and distribution of active pharmaceutical ingredients (APIs), intermediates, and finished dosage forms. The company operates three core business pillars: API production, Contract Development and Manufacturing Organization (CDMO) services, and finished drug products. Its therapeutic focus includes cardiovascular, anti-infective, anti-viral, and oncology treatments. Apeloa utilizes an integrated supply chain to deliver chemical and biological solutions to a global client base. The organization maintains compliance with international quality standards, including certifications from the FDA, EMA, and PMDA. Its CDMO services encompass the full product lifecycle, from process chemistry and analytical development to large-scale commercial manufacturing, supported by specialized technology platforms such as continuous flow chemistry and enzymatic synthesis.

Recent filings

Filing Released Lang Actions
第七届董事会第十七次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at a board meeting of 普洛药业股份有限公司 (Puloyao Pharmaceutical Co., Ltd.). It includes details about the meeting date, attendance, and voting results on several agenda items such as approval of the 2019 Q3 report text, increase in related party transaction limits, merger of subsidiaries, and guarantees for subsidiaries. The document is an official announcement of board decisions rather than the full quarterly report itself. It is not a full financial report but a board/management information announcement about decisions made. Therefore, the appropriate classification is Board/Management Information (MANG). The document length is short and it contains voting results and resolutions from a board meeting, consistent with MANG filings.
2019-10-17 Chinese
2019年第三季度报告正文
Interim / Quarterly Report Classification · 100% confidence The document is titled as the "2019 Third Quarter Report" of the company 普洛药业股份有限公司. It contains detailed financial data for the third quarter of 2019, including income, profit, assets, liabilities, cash flows, shareholder information, and other financial metrics. The presence of comprehensive financial statements and analysis for a period shorter than a full fiscal year (quarterly data) indicates this is an Interim / Quarterly Report. There is no indication that this is merely an announcement or a certification, and the document length and content confirm it is the full report itself, not just a notice or summary. Therefore, the appropriate classification is Interim / Quarterly Report (IR). 9M 2019
2019-10-17 Chinese
2019年前三季度业绩预告
Earnings Release Classification · 95% confidence The document is a performance forecast for the first three quarters of 2019, including estimated net profit and earnings per share, with a clear statement that the data is unaudited and preliminary. It explicitly states that detailed data will be disclosed in the company's 2019 third quarter report. This type of document is a forward-looking earnings preview, not a full financial report. It is an earnings release announcing expected quarterly financial results, not the full interim report itself. The document length is short (994 characters), and it contains key highlights of financial performance for a specific period (Q3 2019). Therefore, it fits the definition of an Earnings Release (ER). 9M 2019
2019-09-26 Chinese
关于公司左乙拉西坦片拟中选联盟地区集中采购的公告
Capital/Financing Update Classification · 90% confidence The document is an announcement by 普洛药业股份有限公司 regarding the company's proposed selection in a regional centralized procurement of a pharmaceutical product (左乙拉西坦片). It details the product, procurement quantity, price, and potential impact on the company. The document is short (1049 characters) and serves as a formal public notice about a business development related to procurement and sales, not a financial report or detailed management discussion. It does not contain financial statements, earnings data, or regulatory certifications. It is not a report publication announcement since it does not mention any report being published or attached. The content fits best with a Capital/Financing Update (CAP) as it relates to a significant business contract and market expansion that could affect company operations and financials in the future.
2019-09-24 Chinese
关于公司全资子公司以自有闲置资金购买理财产品的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by a company about its wholly-owned subsidiary using idle funds to purchase financial products. It details the product type, investment amount, risk analysis, and control measures. It references board meeting approvals and shareholder meeting resolutions but does not contain financial statements or comprehensive financial performance data. The document is relatively short (2067 characters) and serves as a disclosure of a specific financing activity rather than a full financial report or earnings release. Therefore, it fits best under Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes.
2019-09-24 Chinese
关于获得药品注册批件的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement from 普洛药业股份有限公司 regarding the receipt of a drug registration approval from the National Medical Products Administration (国家药品监督管理局). It details the drug name, specifications, registration classification, approval numbers, and the impact on the company. The document is short (1138 characters) and serves as an official announcement of a regulatory approval event rather than a financial report or detailed management discussion. There is no financial data, no mention of earnings, no board changes, no voting results, and no detailed report attached or referenced. This fits the category of a Regulatory Filing (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories.
2019-09-10 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.